<a href="https://www.fiercehealthcare.com/payers/pcma-unveils-new-policy-platform-aimed-drug-affordability" hreflang="en">PCMA unveils new policy platform aimed at drug affordability</a>
The Pharmaceutical Care Management Association (PCMA) has introduced a new policy platform aimed at reducing drug costs, proposing six strategies that focus on increasing competition among drug manufacturers and enhancing transparency within the pharmaceutical supply chain. Key recommendations include limiting anti-competitive practices, shortening the exclusivity period for biologics, and promoting the use of electronic tools to inform patients about lower-cost medication options.
The PCMA's new policy platform proposes actionable reforms such as reducing the monopoly period for biologic therapies to encourage biosimilar adoption and increasing pricing transparency from drug wholesalers. For a healthtech professional, especially those interested in AI drug discovery, this signals potential opportunities in developing biosimilars and digital tools for pricing transparency and medication management that align with legislative trends focused on affordability and competition in the pharmaceutical supply chain.